(Q34628304)

3 August 2017

1 reference

title

Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics (English)

1 reference

3 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

Leslie Citrome

1

0 references

language of work or name

English

0 references

publication date

1 March 2011

1 reference

3 August 2017

published in

Postgraduate Medicine

1 reference

3 August 2017

volume

123

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

153-162

1 reference

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

Using oral ziprasidone effectively: the food effect and dose-response

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.03.2273

21 January 2018

Identifiers

DOI

10.3810/PGM.2011.03.2273

1 reference

3 August 2017

1 reference